Investing in the Functional Human Genome
Phaeno is developing PSeq to make full-length, isoform-resolved RNA measurement practical on short-read NGS instruments already used at scale. The opportunity is to move transcriptomics beyond collapsed gene counts and expose RNA-level biology for studies of phenotype and therapeutic response, with outputs structured for machine-learning-driven discovery.
Why now
Short-read sequencing infrastructure is mature, but biology increasingly demands molecule-level transcript resolution. PSeq is designed to close that gap without requiring specialized long-read instruments.
What is different
PSeq combines chemistry and software to recover full-length RNA information, quantify individual molecules, and produce isoform-level feature matrices designed for downstream ML models and established analysis tools.
Current stage
Phaeno has raised $1.4M to date and is engaging qualified investors who can help accelerate validation, commercialization, and platform adoption.
Investor inquiries
Qualified investors interested in Phaeno's mission can email us to start a conversation.